Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Cannabis Sector's Linton, Shark Tank's O'Leary Banking On Psychedelic Meds

By (Brenda O'Farrell/ 15, 2019 02:28AM ET
Cannabis Sector's Linton, Shark Tank's O'Leary Banking On Psychedelic Meds
By (Brenda O'Farrell/   |  Oct 15, 2019 02:28AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Bruce Linton, arguably one of the biggest names in the cannabis industry, is making moves in what he believes is the next big space in the pharmaceutical sector – next-generation psychedelic-inspired medicines.

In an interview with, the founder and former CEO of Canopy Growth (NYSE:CGC), (TSX:WEED) explained why he has become a private investor in a Canadian-based neuro-pharmaceutical company, Mind Medicine Inc., which aims to develop psychedelic inspired medicines, which, according to the latest research, have shown great potential in treating opioid addiction, depression and post-traumatic stress.

Linton called psychedelic-inspired medicine “the next frontier, where medicine is going to put a lot of effort and thought.”

Parallels With Cannabis Industry

Linton sees parallels with the cannabis sector, explaining that best practices and governance will play a big role.

The company, also known as MindMed, last month announced it has closed a strategic investment round, raising US$6.2 million (C$8.2 million) in funding. Linton is just one of the big-name investors it has attracted. The former Canopy Growth CEO said he has recently bought an “8-to-10% stake” in the company, what he described as “a serious six-figure, not-quite-seven-figure” investment. He was also named to the board of directors.

But Psychedelic Meds Are Different

Another big-name investor is Canadian businessman Kevin O’Leary, who is perhaps best known as a cast member of ABC’s Shark Tank. Although he shares Linton’s enthusiasm for the medical breakthrough potential for psychedelic-inspired treatments for opioids and other addictions, he embraces the differences.

O’Leary hasn't invested in any cannabis company, explaining he never wanted to be part of the recreational side of that sector. Psychedelics is different, he said during an interview from Las Vegas recently. MindMed has no interest in the recreational market. It is focusing solely on FDA-approved medicines.

“That I can endorse,” O’Leary said. “That I can invest in.”

“The opioid crisis is affecting millions of American families and it is costing the country $500 billion (C$661.5 million) a year. We owe it to those families to explore all options and find a solution,” O’Leary explained. He said:

“I invested in MindMed because they are approaching psychedelics through rigorous science and FDA trials. The psychedelics space is vastly different than cannabis and legalized recreational use will never happen; psychedelics need to be approved as FDA drugs.”

The opioid crisis is a huge societal problem, he said. But psychedelics is doing something else:

“This is creating medicine that will help people.”

Sizeable Position

O’Leary has taken what he describes as a “sizeable position” in the company, but refused to be specific.

According to MindMed’s founder and director, JR Rahn, the company is currently preparing for two Phase II trials that will begin in 2020.

“It’s the ambition of the company to be a public company by the end of the year,” he said in an interview from Toronto.

The focus of the company as been the 18-MC molecule, which it has synthesized from the psychedelic ibogaine. It is a non-hallucinogenic substance. The aim is to use it as a treatment for opioid addiction. Once it receives FDA approval, the company will then look at other markets.

“There is a renaissance opportunity here,” Rahn said, adding:

“There is a sea change on how we look at these substances as a therapeutic medicine that creates wellness.”

And he is looking for people like Linton to help steer the company to that end. “Bruce is a pioneer. He created the cannabis industry,” Rahn said. “There is a lot of learning on that history.”

Hexo Shares Plummet On Revenue Revisions

Shares of Hexo Corp (NYSE:HEXO), (TSX:HEXO) lost 6.72% in New York on Monday, continuing its losses from last week after the Quebec-based cannabis grower announced a fourth-quarter revenue warning in advance of its next financial earnings report.

In an update last Thursday, Hexo said its fourth-quarter revenue will come in somewhere between C$14.5 million (US$10.96 million) and C$16.5 million (US$11.04 million). That is a substantial reduction from predictions last June that had Hexo’s fourth-quarter results showing revenues that would be double its third-quarter figures of C$13 million (US$9.83 million).

Hexo Weekly
Hexo Weekly

The reaction was swift. Hexo’s shares dropped almost 23%. Markets in Canada were closed Monday for the Thanksgiving holiday.

Last week, Hexo also withdrew its forecast for fiscal 2020 results. It had previously expected fiscal 2020 net revenues to hit C$400 million (US$302.36 million). The withdrawal of the forecast also comes about one week after the company’s chief financial officer Michael Monahan resigned.

Hexo’s next earnings report will be released on Oct. 24.

Cannabis Sector's Linton, Shark Tank's O'Leary Banking On Psychedelic Meds

Related Articles

Cannabis Sector's Linton, Shark Tank's O'Leary Banking On Psychedelic Meds

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
DJ DenSetiawan
DJ DenSetiawan Oct 15, 2019 1:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I read the info, So said for this.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email